Thromb Haemost 1989; 61(01): 106-110
DOI: 10.1055/s-0038-1646536
Original Article
Schattauer GmbH Stuttgart

Significance of Plasma Adenosine in the Antiplatelet Activity of Forskolin: Potentiation by Dipyridamole and Dilazep

Kailash C Agarwal
The Section of Biochemical Pharmacology, Division of Biology and Medicine, Brown University, Providence, RI, USA
,
Beth A Zielinski
The Section of Biochemical Pharmacology, Division of Biology and Medicine, Brown University, Providence, RI, USA
,
Ranjan S Maitra
The Section of Biochemical Pharmacology, Division of Biology and Medicine, Brown University, Providence, RI, USA
› Author Affiliations
Further Information

Publication History

Received 26 May 1988

Accepted after revision 29 September 1988

Publication Date:
24 July 2018 (online)

Summary

Forskolin, a plant (Coleus forskohlii) diterpene, inhibits ADP- induced (human: IC50, 2.3±1.0 μ;M; rat: IC50, 1.2±0.5 μM) and collagen-induced (human: IC50, 2.4±1.2 μM; rat: 0.6±0.2 μM) platelet aggregation in human and rat platelet-rich plasma (PRP). Human blood levels of adenosine (Ado) are low (100-300 nM) as compared to levels in rat plasma (7.55 ± 0.51 μM). Ado is a natural antiplatelet and vasodilatory agent produced by vascular endothelium, heart and other body tissues. If the plasma Ado is degraded by pretreatment of PRP with adenosine deaminase (ADA), forskolin inhibition on platelet aggregation is reduced by 2-4 fold both in human and rat blood. On the other hand, if the physiological steady state levels of Ado are maintained by collecting the blood in the presence of the inhibitors of ADA (2’-deoxycoformycin, dCF, 5 μM) and Ado uptake (dipyridamole, 10 μM or dilazep, 2 μM), forskolin inhibition (IC50, 3.2 μM) on platelet aggregation in human PRP is potentiated by 20-40 fold (IC50, 0.075-0.15 μM). Similar potentiated forskolin effect (IC50, 0.53 μM) is seen if the ADA-treated human PRP is replenished with a low level of Ado (50 nM) after ADA inactivation by dCF and Ado-uptake blockade by dilazep. If the plasma is replenished with a higher concentration of Ado (300 nM), greater potentiation is seen (IC50, 0.23 μM). Forskolin is 2-4 fold more inhibitory in rat PRP than in human PRP, partially due to the presence of higher levels of Ado in the rat plasma. These studies demonstrate an important role of plasma Ado in the antiplatelet activity of forskolin and this effect can be greatly potentiated by the clinically used drugs, dipyridamole and dilazep.

 
  • References

  • 1 Siegl AM, Daly JW, Smith JB. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Mol Pharmacol 1982; 21: 680-687
  • 2 Agarwal KC, Parks Jr RE. Synergistic inhibition of platelet aggregation by forskolin plus PGE1 or 2-fluoroadenosine: Effects of 2’ ,5’-dideoxyadenosine and 5’-methylthioadenosine. Biochem Pharmacol 1982; 31: 3713-3716
  • 3 Seamon K, Daly JW. Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem 1981; 256: 9799-9801
  • 4 Insel PA, Stengel D, Ferry N, Hanoune J. Regulation of adenylate cyclase of human platelet membranes by forskolin. J Biol Chem 1982; 257: 7485-7490
  • 5 FitzGerald GA. Drug therapy: dipyridamole. New Engl J Med 1987; 316: 1247-1257
  • 6 Dresse A, Chevolet C, Delapierre D, Masset H, Weisenberger H, Bozier G, Heinzel G. Pharmacokinetics of oral dipyridamole (persan- tine) and its effects on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982; 23: 229-234
  • 7 Lenke D, Brock N, Zechel HJ. Zur Pharmakologie von 1,4-bis-[3-(3,4,5-trimethoxybenzoyl-oxy)-propyl]-perhydro-1,4-diazepin (dilazep I.N.N.), einer neuen koronaraktiven Substanz. Arzneim-Forsch (Drug Res) 1972; 22: 639-651
  • 8 Sollevi A, Torsell L, Owall A, Edlund A, Lagerkranser M. Levels and cardiovascular effects of adenosine in humans. In: Topics and Perspectives in Adenosine Research. Garlach E, Becker BF. (eds) Springer-Verlag; Heidelberg: 1987. pp 599-613
  • 9 Pohl VJ, Brock N. Vergleichende Untersuchungen zur Hemmung des Adenosinabbaus in vitro durch Dilazep. Arzneim-Forsch (Drug Res) 1974; 24: 1901-1905
  • 10 Dawicki DD, Agarwal KC, Parks Jr RE. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233. Thromb Res 1986; 43: 161-175
  • 11 Dawicki DD, Agarwal KC, Parks Jr RE. Adenosine metabolism in human whole blood: Effects of nucleoside transport inhibitors and phosphate concentration. Biochem Pharmacol 1988; 37: 621-626
  • 12 Drury A, Szent-Gyorgi A. The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J Physiol. (London): 1929. 68 213-237
  • 13 Born GV R, Haslam RJ, Goldman M, Lowe RD. Comparative effectiveness of adenosine analogues as inhibitors of blood-platelet aggregation and as vasodilators in man. Nature 1965; 205: 678-680
  • 14 Agarwal KC. Adenosine and platelet function. In: Role of Adenosine in Cerebral Metabolism and Blood Flow. Stefanovich V, Okyayuz-Baklouti I. (eds) VSP BV Press; Utrecht: 1988. pp 107-124
  • 15 Agarwal KC. New insights into the antiplatelet activity of forskolin: Role of plasma adenosine and species differences. Thromb Haemostas 1987; 58: 212 (Abstr)
  • 16 Agarwal KC, Haskel EJ, Parks Jr RE. Effects of adenosine analogs and adenine nucleotides on adenosine-5’-diphosphate-induced rat platelet aggregation. Biochem Pharmacol 1980; 29: 1799-1805
  • 17 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
  • 18 Cardinal DC, Flower RJ. The electronic aggregometer: A novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3: 135-158
  • 19 Sato T, Ui M. A sensitive radioimmunoassay for adenosine. In: Physiology and Pharmacology of Adenosine. Daly JW, Kuroda Y, Phillis JW, Shimizu H, Ui M. (eds) Raven Press; New York: 1983. PP 1-11
  • 20 Paterson AR P, Jackobs ES, Harley ER, Fu N, Robins MJ, Cass CE. Inhibition of nucleoside transport. In: Regulatory Functions of Adenosine. Berne RM, Rail TW, Rubio R. (eds) Martinus Nijhoff Publishers; The Hague: 1983. pp 203-220
  • 21 Pearson JD, Hellewell PG, Gordon JL. Adenosine uptake and adenine nucleotide metabolism by vascular endothelium. In: Regulatory Functions of Adenosine. Berne RM, Rail TW, Rubion R. (eds) Martinus Nijhoff Publishers; The Hague: 1983. pp 333-345
  • 22 Berne RM, Winn HR, Knabb RM, Ely SW, Rubio R. Blood flow regulation by adenosine in heart, brain and skeletal muscle. In: Regulatory Functions of Adenosine. Berne RM, Rail TW, Rubio R. (eds) Martinus Nijhoff Publishers; The Hague: 1983. pp 293-317
  • 23 Dubey MP, Srimal RC, Nityanand S, Dhawan BN. Pharmacological studies on coleonol, a hypotensive diterpene from Coleus forskohlii. J Ethnopharmacol 1981; 3: 1-13
  • 24 Agarwal KC, Buckley RS, Parks Jr RE. Role of plasma adenosine in the antiplatelet action of HL-725, a potent inhibitor of cAMP phosphodiesterase: species differences. Thromb Res 1987; 47: 191-200
  • 25 Jarvis SM, Hammond JR, Paterson AR P, Clanachan AS. Species differences in nucleoside transport: A study of uridine transport and nitrobenzylthioinosine binding by mammalian erythrocytes. Biochem J 1983; 208: 83-88